Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically
relevant tumor-targeting immune responses, which critically rely on the antigenicity of …

Fifty years since the initial discovery of HMGB1 in 1973 as a structural protein of chromatin,
HMGB1 is now known to regulate diverse biological processes depending on its subcellular …

Although it was thought that apoptotic cells, when rapidly phagocytosed, underwent a silent
death that did not trigger an immune response, in recent years a new concept of …

During long standing hyperglycaemic state in diabetes mellitus, glucose forms covalent
adducts with the plasma proteins through a non-enzymatic process known as glycation …

Multicellular animals detect pathogens via a set of receptors that recognize pathogen-
associated molecular patterns (PAMPs). However, pathogens are not the only causative …

Advanced glycation end-products are a complex and heterogeneous group of compounds
that have been implicated in diabetes related complications. At present it is not known if they …

Pathogen‐associated molecular pattern molecules (PAMP s) are derived from
microorganisms and recognized by pattern recognition receptor (PRR)‐bearing cells of the …

Advanced glycation end products (AGEs) are proteins or lipids that become glycated after
exposure to sugars. AGEs are prevalent in the diabetic vasculature and contribute to the …

High-mobility group box 1 protein (HMGB1), which previously was thought to function only
as a nuclear factor that enhances transcription, was recently discovered to be a crucial …

Complex genetic and physiological variations as well as environmental factors that drive
emergence of chromosomal instability, development of unscheduled cell death, skewed …